Vanguard Group Inc Bio Atla, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Bio Atla, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,099,037 shares of BCAB stock, worth $3.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,099,037

Previous 2,081,370 0.85%

Holding current value

$3.21 Million

Previous $5.12 Million 41.02%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.88 - $3.46 $33,213 - $61,127	17,667 Added 0.85%	2,099,037 $7.22 Million
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $26,601 - $66,608	-20,946 Reduced 1.0%	2,081,370 $5.12 Million
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $7,847 - $14,171	4,616 Added 0.22%	2,102,316 $3.57 Million
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $493,339 - $674,637	174,325 Added 9.06%	2,097,700 $6.29 Million
Q1 2023 May 15, 2023	SELL	$2.3 - $8.25 $17,627 - $63,228	-7,664 Reduced 0.4%	1,923,375 $5.15 Million

Q4 2022 Feb 10, 2023	BUY	$7.63 - $11.01 $3.99 Million - $5.76 Million	522,807 Added 37.13%	1,931,039 $15.9 Million
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $774,975 - $3.13 Million	263,597 Added 23.03%	1,408,232 $10.8 Million
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $876,808 - $2.21 Million	-411,647 Reduced 26.45%	1,144,635 $3.26 Million
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $3.1 Million - $13.3 Million	-708,372 Reduced 31.28%	1,556,282 $7.78 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $3.34 Million - $5.44 Million	175,631 Added 8.41%	2,264,654 $44.5 Million
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $30.7 Million - $45.5 Million	1,041,111 Added 99.35%	2,089,023 $61.5 Million
Q2 2021 Aug 13, 2021	BUY	$38.07 - $56.17 $39.9 Million - $58.9 Million	1,047,912 New	1,047,912 $44.4 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $55.5M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Bio Atla, Inc. Transaction History